SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance
SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance
Summary SARS-CoV-2 Lambda, a new variant of interest, is now spreading in some South American countries; however, its virological features and evolutionary trait remain unknown. Here we reveal that the spike protein of the Lambda variant is more infectious and it is attributed to the T76I and L452Q mutations. The RSYLTPGD246-253N mutation, a unique 7-amino-acid deletion mutation in the N-terminal domain of the Lambda spike protein, is responsible for evasion from neutralizing antibodies. Since the Lambda variant has dominantly spread according to the increasing frequency of the isolates harboring the RSYLTPGD246-253N mutation, our data suggest that the insertion of the RSYLTPGD246-253N mutation is closely associated with the massive infection spread of the Lambda variant in South America. HighlightsLambda S is highly infectious and T76I and L452Q are responsible for this propertyLambda S is more susceptible to an infection-enhancing antibodyRSYLTPGD246-253N, L452Q and F490S confer resistance to antiviral immunity Graphical Abstractbiorxiv;2021.07.28.454085v1/UFIG1F1ufig1
Tokunaga Kenzo、Yamasoba Daichi、Tanaka Yuri L、Kazuma Yasuhiro、Arase Hisashi、Nomura Ryosuke、Takaori-Kondo Akifumi、The Genotype to Phenotype Japan (G2P-Japan) Consortium、Nakagawa So、Shirakawa Kotaro、Butlertanaka Erika P、Kimura Izumi、Wu Jiaqi、Horisawa Yoshihito、Liu Yafei、Kosugi Yusuke、Sato Kei、Saito Akatsuki
Department of Pathology, National Institute of Infectious DiseasesDivision of Systems Virology, Department of Infectious Disease Control, International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo||Faculty of Medicine, Kobe UniversityDepartment of Veterinary Science, Faculty of Agriculture, University of MiyazakiDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto UniversityDepartment of Immunochemistry, Research Institute for Microbial Diseases, Osaka University||Laboratory of Immunochemistry, World Premier International Immunology Frontier Research Centre, Osaka University||Center for Infectious Disease Education and Research, Osaka UniversityDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto UniversityDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto UniversityDepartment of Molecular Life Science, Tokai University School of Medicine||CREST, Japan Science and Technology Agency||Bioinformation and DDBJ Center, National Institute of GeneticsDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto UniversityDepartment of Veterinary Science, Faculty of Agriculture, University of MiyazakiDivision of Systems Virology, Department of Infectious Disease Control, International Research Center for Infectious Diseases, The Institute of Medical Science, The University of TokyoDepartment of Molecular Life Science, Tokai University School of Medicine||CREST, Japan Science and Technology AgencyDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto UniversityDepartment of Immunochemistry, Research Institute for Microbial Diseases, Osaka University||Laboratory of Immunochemistry, World Premier International Immunology Frontier Research Centre, Osaka UniversityDivision of Systems Virology, Department of Infectious Disease Control, International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo||Laboratory of Systems Virology, Institute for Frontier Life and Medical Sciences, Kyoto University||Graduate School of Pharmaceutical Sciences, Kyoto UniversityDivision of Systems Virology, Department of Infectious Disease Control, International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo||CREST, Japan Science and Technology AgencyDepartment of Veterinary Science, Faculty of Agriculture, University of Miyazaki||Center for Animal Disease Control, University of Miyazaki||Graduate School of Medicine and Veterinary Medicine, University of Miyazaki
基础医学生物科学现状、生物科学发展分子生物学
SARS-CoV-2COVID-19spike proteinC.37Lambda
Tokunaga Kenzo,Yamasoba Daichi,Tanaka Yuri L,Kazuma Yasuhiro,Arase Hisashi,Nomura Ryosuke,Takaori-Kondo Akifumi,The Genotype to Phenotype Japan (G2P-Japan) Consortium,Nakagawa So,Shirakawa Kotaro,Butlertanaka Erika P,Kimura Izumi,Wu Jiaqi,Horisawa Yoshihito,Liu Yafei,Kosugi Yusuke,Sato Kei,Saito Akatsuki.SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance[EB/OL].(2025-03-28)[2025-08-02].https://www.biorxiv.org/content/10.1101/2021.07.28.454085.点此复制
评论